Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer

Journal of Oncology Practice

Volumn 10, Issue 5, 2014, Pages 308-314

  Dotan, Efrat ^a   Li, Tianyu ^a   Hall, Michael J ^a   Meropol, Neal J ^a   Beck, J Robert ^a   Wong, Yu Ning ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COLORECTAL CANCER; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOLOGIST; PRACTICE GUIDELINE; ALGORITHM; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; FACTUAL DATABASE; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASMS; ONCOGENE RAS; ONCOLOGY; PROCEDURES; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; FEMALE; GENES, RAS; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84911881319     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.001439     Document Type: Article

References (33)

1. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
2. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
3. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
4. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005
5. Meropol NJ: Epidermal growth factor receptor inhibitors in colorectal cancer: It's time to get back on target. J Clin Oncol 23:1791-1793, 2005
6. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
7. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol. 22:1535-1546, 2011
8. Van Cutsem E, Lang I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26, 2008 (suppl; abstr 2)
9. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
10. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
11. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
12. Javle M, Hsueh CT: Updates in gastrointestinal oncology: Insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2:9, 2009.
13. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
14. Neugut AI, Becker DJ, Insel BJ, et al: Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer. J Oncol Pract 8:156-163, 2012
15. Hershman DL, Wilde ET, Wright JD, et al: Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol 30:806-812, 2012
16. Dranitsaris G, Evans WK, Milliken D, et al: The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer. J Eval Clin Pract 11:350-356, 2005
17. Nguyen PL, Gu X, Lipsitz SR, et al: Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517-1524, 2011
18. Shirvani SM, Pan IW, Buchholz TA, et al: Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer 117:4595-4605, 2011
19. Smith BD, Pan IW, Shih YC, et al: Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103:798-809, 2011
20. Lang K, Sussman M, Friedman M, et al: Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 135:582-588, 2009
21. Crawford ED, Black L, Eaddy M, et al: A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 13:162-167, 2010
22. Hatoum HT, Lin SJ, Smith MR, et al: Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer 11:177-183, 2011
23. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
24. Zafar SY, Marcello JE, Wheeler JL, et al: Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 5:228-233, 2009
25. Weir MA, Gomes T, Winquist E, et al: Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents. J Oncol Pract 8:179-183, 2012
26. Hassett MJ, Silver SM, Hughes ME, et al: Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30:2218-2226, 2012
27. Hauptman PJ, Schnitzler MA, Swindle J, et al: Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA 296:1877-184, 2006
28. Wong YN, Meropol NJ, Speier W, et al: Cost implications of new treatments for advanced colorectal cancer. Cancer 115:2081-2091, 2009
29. Mittmann N, Au HJ, Tu D, et al: Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO. 17 trial. J Natl Cancer Inst 101:1182-1192, 2009
30. Vijayaraghavan A, Efrusy MB, Göke B, et al: Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 131:438-445, 2012
31. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 25, 2007 (suppl; abstr 4013)
32. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
33. Blanke CD, Goldberg RM, Grothey A, et al: KRAS and colorectal cancer: Ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist 16:1061-1068, 2011